IngredientsPapain is a plant-derived proteolytic enzyme belonging to the cysteine protease family. It has attracted sustained interest across food science, pharmacy, wound care, and nutritional supplementation due to its potent protein-digesting ability and broad biochemical stability. This article covers its identity, historical use, biochemistry, clinical evidence, dosage forms, and safety profile.
Carica papaya, commonly referred to as papaya, is a member of the Caricaceae family, with a diverse array of compounds and biomolecules, notably papain, with significant industrial and medicinal value. Carica papaya (melon tree) belongs to the family Caricaceae, order Violales, and produces large, juicy fruits known as papayas; the papaya originally comes from tropical regions, where it was also cultivated.
Papain is a plant-derived cysteine protease of approximately 23.4 kDa extracted from the latex of the papaya tree (Carica papaya) that digests protein substrates and has long uses in food processing, topical enzymatic wound debridement, and as an oral digestive enzyme supplement. Papain (EC 3.4.22.2) belongs to the cysteine protease family, the same family as bromelain, and functions by hydrolyzing peptide bonds in proteins. It is also designated under the pharmacopoeial name papainum, and its synonyms include papaya proteinase I, papaya protease I, and papayotin.
Papain is an enzyme present in the leaves, latex, roots, and fruit of the papaya plant (Carica papaya) that catalyzes the breakdown of proteins by hydrolysis. However, it is primarily extracted from the latex of unripe Carica papaya fruit.
Commercial "papain" is frequently not a single isolated enzyme but rather a complex of related cysteine proteases. The food enzyme under this designation is a cysteine endopeptidase complex containing four proteolytic activities: papain, chymopapain, caricain, and glycyl endopeptidase. The latex from unripe papaya fruit is rich in two principal enzymes — papain (also known as "vegetable pepsin") and chymopapain — along with other cysteine endopeptidases, such as papaya endopeptidase II (caricain), papaya endopeptidase IV, omega endopeptidase, chitinases, protease inhibitors, linamarase, and proteins without known functions. As the fruit ripens, papain and chymopapain dissipate and neither is present in the ripe fruit. Cysteine proteinases may constitute as much as 80% of the enzyme portion in papaya latex.
Papain is commercially provided as a partially purified crystalline form or as crude papain, the latter being a mixture comprising papain, chymopapain, and lysozyme.
The latex is obtained by scoring (making shallow incisions) on the surface of unripe papaya fruits; the milky sap exudes naturally and is collected in small trays or containers. The latex is immediately dried under controlled conditions — traditionally sun-dried but now often vacuum- or spray-dried — to preserve enzymatic activity. Dried latex typically contains 5–8% active papain, along with chymopapain, peptidases, and minor plant proteins.
Modern extraction, purification, and stabilization techniques have refined papain into a standardized, high-activity commercial enzyme, available in powder, granule, or liquid forms. Dietary supplement preparations take the form of capsules, tablets, or blended digestive enzyme powders. Topical pharmaceutical preparations have historically included gels, ointments, and creams, often in combination with urea.
Papaya's medicinal applications were noted among indigenous peoples of Mesoamerica for digestive and topical remedies prior to its spread to other regions following European contact in the 16th century. Papaya has a long history of use in traditional medicine across various cultures; indigenous communities in Central and South America utilized papaya fruit and its enzyme-rich latex for digestive ailments, wound healing, and more.
In traditional medical cultures, papayas — including peel, fruit pulp, seed, and rarely leaves and latex — were primarily used to treat asthma, parasitoses, wound healing disorders, and gastrointestinal problems such as diarrhoea or constipation. Papain was used to prevent burn infections, defibrinate wounds, treat insect bites, treat oedema and inflammatory processes, promote wound healing, and — in low dosages — in the event of stomach upsets.
Traditional cultures in Hawaii and Tahiti made poultices out of the skins of papaya, as this part of the fruit has a particularly high concentration of papain. Traditional healers applied this substance to the skin to heal wounds, burns, rashes, and insect stings. In Polynesian cultures, including Hawaii and other Pacific islands, the enzyme-rich fruit was used to ease stomach discomfort, bloating, and digestive irregularities.
Papaya is known as a traditional remedy for gastrointestinal complaints in countries where it grows. In Ayurvedic medicine, the latex is used to relieve dyspepsia, while the fruit is applied as a stomachic and digestive.
In pre-19th-century traditional use in tropical regions, papaya latex was applied as topical poultices for wounds, and unripe papaya fruit was used to tenderize meat. Historically, people harvested this enzyme by slashing the skin of unripe papayas and collecting the resulting sticky, latex-like sap. People could also cook with unripe papayas, relying on the green papaya to break up in the cooking process and release the enzyme, or certain leaves could be added to a recipe to soften the meat.
In 1879, the enzyme was first identified and named papain after its botanical source, Carica papaya. By the early 20th century, researchers had successfully extracted and characterized papain, identifying it as a cysteine protease — an enzyme dependent on a reactive cysteine residue in its active site to cleave peptide bonds. Isolation and purification protocols were developed in the 1920s–1950s; the catalytic cysteine was identified and structure–function relationships were clarified during the 1950s–1970s; and from the 1980s–2000s, papain was included in topical debriding products (papain–urea) and recombinant expression was explored. With the advent of industrial biotechnology in the 1950s and 1960s, papain found growing applications in food processing, pharmaceuticals, and leather industries, as its ability to hydrolyze complex proteins under mild conditions made it a favored alternative to animal proteases like pepsin and trypsin.
Papain is referred to as papaya protease and is renowned for its broad substrate specificity, stability over a wide pH range, and ability to catalyze reactions under mild, eco-friendly conditions. It exhibits both endopeptidase and exopeptidase activity, making it highly versatile for partial or complete hydrolysis of complex proteins.
Beyond the principal enzyme, the food enzyme complex contains papain (EC 3.4.22.2), chymopapain (EC 3.4.22.6), caricain (EC 3.4.22.30), and glycyl endopeptidase (EC 3.4.22.25), obtained from the latex of unripe Carica papaya. Papain is primarily a mixture of protein-degrading enzymes, but other components of papain can degrade carbohydrates and fats.
Within C. papaya, a spectrum of bioactive compounds has been identified, encompassing alkaloids, tannins, phenolics, flavonoids, saponins, terpenoids, sugars, glycosides, amino acids, steroids, and the pivotal enzyme papain. However, the present article focuses on papain as the enzymatically active constituent of primary pharmacological and nutritional relevance.
Cysteine proteases contain a Cys-His pair in their active site, and their catalytic activation involves a cysteine sulfhydryl group. Deprotonation of the cysteine sulfhydryl by an adjacent histidine residue is followed by nucleophilic attack of the cysteine on the peptide carbonyl carbon. A thioester linking the new carboxy-terminus to the cysteine thiol is an intermediate of the reaction, comparable to the acyl-enzyme intermediate of a serine protease. More specifically, in the active site of papain, Cys-25 and His-159 are thought to be catalytically active as a thiolate-imidazolium ion pair.
The name "cysteine protease" refers to the protease's nucleophilic cysteine residue that forms a covalent bond with the carbonyl group of the scissile peptide bond in substrates. The papain-like cysteine proteases, classified as the "C1 family," are the most predominant cysteine proteases, found in viruses, plants, primitive parasites, invertebrates, and vertebrates alike.
Papain is a cysteine hydrolase that is stable and active under a wide range of conditions and is very stable even at elevated temperatures. The enzyme has been reported to have a high optimal temperature of 65°C and a wide pH range of 5–8 for its activity. Separately, papain is active over a pH range of 3 to 12 under certain assay conditions. Papain is highly stable at pH 4–11 and 37–60°C as assessed via azocasein assay.
Native pure papain is partially reactive until activated upon by mild reducing agents such as cysteine, at the free SH functional group thereof.
Papain acts extracellularly to hydrolyze proteins, including fibrin and denatured collagen. Papain, the proteolytic enzyme from the fruit of Carica papaya, is a potent digestant of nonviable protein matter but is harmless to viable tissue. This substrate selectivity underlies its usefulness in wound debridement: the enzyme preferentially degrades denatured, necrotic, or cross-linked proteins while leaving intact cellular architecture relatively unaffected.
Papain is relatively ineffective when used alone as a debriding agent and requires the presence of activators to stimulate its digestive potency. In the papain-urea formulation, papain is combined with urea, a denaturant of proteins, to bring about two supplemental chemical actions: to expose by solvent action the activators of papain, and to denature the nonviable protein matter in lesions, thereby rendering it more susceptible to enzymatic digestion. Pharmacologic studies have shown that the combination of papain and urea results in twice as much digestive activity as papain alone.
Fibrin zymography demonstrated that papain has fibrinolytic activity, displaying efficacy in degrading fibrin, indicating its potential as a fibrinolytic enzyme. However, despite the potential therapeutic benefits of cysteine proteases for cardiovascular illnesses, there is a lack of significant human and animal trials to thoroughly investigate these effects.
Papain has region-specific effects on gastric motility dependent on its enzymatic activity; based on these findings, papain may be beneficial in functional dyspepsia.
Papain hydrolyzes dietary proteins into peptides and amino acids, aiding digestion in individuals with low protease secretion or dyspepsia. Exogenous papain supplements add luminal proteolytic capacity to digest dietary proteins during gastric and small-intestinal transit. Oral papain has negligible systemic bioavailability; its benefit as a digestive aid is luminal and the clinical evidence is limited.
The most robustly designed clinical trial in this area examined a papaya preparation rather than isolated papain. In a placebo-controlled, randomized, double-blind study, Caricol — a preparation of organically cultivated papaya — was tested on 139 volunteers with functional gastrointestinal complaints and was significantly more effective than placebo in ameliorating constipation, painful strenuous bowel movements, and flatulence.
An oral enzyme supplement from India containing papain was tested on 100 non-ulcer dyspepsia patients and showed a significant reduction in frequency and severity of all recorded symptoms of indigestion. Multi-enzyme blends that include papain improved scores for pain, dyspepsia symptoms, and sleep quality in adults with functional dyspepsia over two months, suggesting a clinically meaningful effect in some patients.
A key limitation is that clinical studies have demonstrated effects of consumption of papaya preparations — including papain and chymopapain — in digestive disorders, with one clinical study (N=126) documenting reductions in self-reported symptoms, particularly constipation, flatulence, and heartburn, following daily consumption of a commercial papaya preparation (Caricol) 20 mL for 40 days. Most studies use whole-papaya preparations rather than isolated, standardized papain, making it difficult to attribute effects specifically to papain. Overall, evidence for the digestive use of oral papain is preliminary and primarily derived from small trials using mixed preparations.
Removing devitalized tissue is recommended in wound treatment, preparing the wound bed before the dressing is applied. Papain is a chemical debriding agent due to its enzymatic action, which provokes the dissociation of protein molecules, dissolving necrotic tissue.
Clinical studies in burn and chronic wound care indicate that papain–urea preparations can effectively remove necrotic tissue and may shorten the time to a clean wound bed when used properly. A clinical study in patients with large burn wounds found that papain–urea debridement was effective in removing dead tissue and generally safe when used properly, though careful monitoring was required.
A systematic review analyzing evidence on the use of papain in the wound healing process identified a lack of a standard form and presentation to use the product, alongside the predominance of low-quality research according to international assessment scales, indicating the need to develop research with stricter methods for a more precise assessment of the effectiveness of papain in the tissue repair process.
Papain has been used in clinical trials and case reports to treat wounds, including pediatric burns. The overall evidence for wound debridement is moderate but methodologically heterogeneous; most supporting data comes from case series and historical clinical reports rather than large, well-controlled randomized trials.
Papain's proteolytic action can reduce the load of damaged proteins and matrix fragments in injured tissue. Animal studies suggest that papain may lessen inflammatory markers and protect the gut lining in models of intestinal injury and inflammation, sometimes tested alongside bromelain. In small human trials, oral proteolytic enzyme combinations that include papain have been investigated for post-surgical swelling and pain, as well as soft-tissue injuries. These human data are preliminary and typically involve multi-enzyme preparations rather than papain alone.
While the pharmacological effects of papain have not been extensively studied compared to its enzymatic activity, it holds potential benefits beyond protein digestion. One study investigated the potential effects of papain against skin inflammation in house dust mite-exposed NC/Nga atopic dermatitis (AD) mice and human HaCaT keratinocytes. Findings indicated that oral intake of papain decreased the severity scores of lesions resembling atopic dermatitis, transepidermal water loss, levels of inflammatory cytokines and serum immunoglobulin E in Dfb-induced AD mice, along with a reduction in epidermal thickness and mast cell infiltration. The NC/Nga mouse model, although appropriate for investigating a specific genetic mutation related to AD, may not entirely replicate human AD; additionally, the HaCaT keratinocyte model has inherent limitations in completely representing the intricate structure of human skin. Clinical trials in humans are required before conclusions can be drawn. This evidence is therefore preclinical only.
The potential role of papain in preventing fibrinogenolytic, anticoagulant, and antithrombotic activities has not been fully investigated. Research has examined how papain influences fibrinogen and the process of blood coagulation. Evidence in this domain currently remains confined to in vitro and animal models; despite the potential therapeutic benefits of cysteine proteases for cardiovascular illnesses, there is a lack of significant human and animal trials to thoroughly investigate these effects.
Caricain, and to a lesser extent chymopapain, from papaya latex are gluten-detoxifying enzymes that may provide a basis for suitable enzyme therapy in gluten intolerance. This is a preliminary research finding and no clinical trials in gluten-intolerant patients using papain-based preparations have been robustly established in the peer-reviewed literature reviewed here.
Laboratory research suggests that exposure to a multi-enzyme preparation containing papain stimulates the production of reactive oxygen species (ROS) and cytokines, potentially having tumoricidal effects. This is in vitro evidence only, and no clinical conclusions can be drawn regarding cancer treatment.
There is no universally accepted FDA/NIH Dietary Reference Intake (DRI) for papain. Common commercial oral doses range from 40 mg to 500 mg per day depending on formulation and claimed activity; many products list enzyme activity units rather than mg. For topical use, formulation-specific papain–urea or papain-gel products supply enzyme concentrations tailored for debridement.
In the gastrointestinal clinical study, a commercial papaya preparation (Caricol) was administered at 20 mL daily for 40 days in a study of 126 patients.
Topical enzymatic debridement gels or creams have used papain at 1–5% concentration.
One USP unit of papain activity is defined as that which releases an equivalent of 1 mg of tyrosine from a casein substrate solution as described in the United States Pharmacopeia reference guide, with activity ranges reported from 10,000 to 100,000 USP units per mg protein in pharmaceutical-grade material.
There are very little data available to make specific recommendations regarding systemic doses of papaya or papain.
Papain as a dietary supplement ingredient is regulated in the United States under the Dietary Supplement Health and Education Act (DSHEA). Specific papain-containing products marketed for disease treatment would be regulated as drugs and require FDA approval.
Regarding topical pharmaceutical use, topical papain–urea products (sold under trade names including Accuzyme, Panafil, and others) were discontinued in the United States. The U.S. Food and Drug Administration ordered companies to stop marketing unapproved drug products containing papain in a topical dosage form, with firms required to stop manufacturing these products by November 24, 2008. Topical drug products containing papain had historically been marketed without approval; the FDA took this action because adverse events reported to the agency raised serious safety concerns.
At the European level, the food enzyme papain (EC 3.4.22.2) is extracted from the latex of unripe Carica papaya by authorized manufacturers and is intended to be used in specific food manufacturing processes, with safety evaluations conducted by the European Food Safety Authority (EFSA).
Several studies have reported occupational rhinitis and asthma in workers of industries where papain is handled. Papain is a known occupational allergen — powdered preparations pose an inhalation risk and can cause respiratory sensitization and occupational asthma. This is the most clinically significant safety signal associated with papain exposure.
Among the four proteins in the cysteine endopeptidase complex, papain and chymopapain are known food allergens. The amino acid sequences of these four proteins present a high degree of homology (62%–81% sequence identity), and using a standardized threshold criterion, matches with six food and eight respiratory allergens were found using the AllergenOnline and COMPARE databases. The EFSA Panel considered that a risk of allergic reactions upon dietary exposure to the food enzyme cannot be excluded.
Administration of chymopapain for chemonucleolysis resulted in sensitization in some patients.
Through January 2008, the FDA received 37 reports of adverse events associated with topical papain products, including cases of potentially life-threatening hypersensitivity reactions. This adverse event record was a primary driver of the 2008 FDA enforcement action withdrawing unapproved topical papain products from the U.S. market.
Although papain is used as a therapeutic alternative for wound healing due to its debridement action in devitalized or necrotic tissues, its use in high doses can induce potential skin irritation and side effects.
A reduction of anticoagulant effect was observed in a patient taking a fermented preparation made from yeast fermentation of papaya, and papaya assumption has been associated with the increase of warfarin effect through the inhibition of platelet aggregation. These case reports, documented in the Italian surveillance system for natural health products, indicate that bidirectional interactions with anticoagulant therapy are possible, though the precise pharmacokinetic basis in the context of isolated papain supplementation has not been fully established.
Hydrogen peroxide should not be used to clean wounds before applying papain-urea preparations, as hydrogen peroxide can make papain-urea less effective in breaking down the tissues of a wound.
The EFSA Panel noted the presence of multiple mycotoxins in all food enzyme batches evaluated, indicating deficiencies in the quality assurance system, highlighting the importance of sourcing from manufacturers with robust quality controls.
Based on the data provided, the origin of the food enzyme being an edible plant source, and the estimated dietary exposure, the EFSA Panel concluded that the food enzyme does not give rise to safety concerns under the intended conditions of use, with the caveat that allergenic risk cannot be fully excluded.
Health conditions that Papain may help support.
The Caricol® RCT (Muss et al., 2013; n=139) demonstrated significant improvements in bloating, constipation, and painful bowel movements in subjects with chronic gastrointestinal dysfunction using 20 mL/day for 40 days. A second clinical study in 150+ subjects with gastritis or IBS found similar improvements in flatulence and abdominal pain. Traditional use of papaya enzyme for digestive discomfort is widely documented.
A double-blind, placebo-controlled clinical study (Muss et al., 2013; PMID 23524622) of 139 volunteers with chronic gastrointestinal dysfunction found the papaya preparation Caricol® improved constipation and bloating significantly; the heartburn endpoint did not reach significance due to a small subgroup (n=13, p=0.114). GoodRx notes some studies suggest papain can help with reflux and heartburn symptoms, but effect sizes are modest. Evidence is real but limited to preparation-level trials rather than isolated papain.
A 2024 study (Antioxidants, PMC11351312) showed papain enhanced expression of antioxidant enzymes in atopic dermatitis models and reduced ROS production in H2O2-damaged human keratinocytes. A study in the Journal of Immunotoxicology confirmed papain's antibacterial, anti-inflammatory, and antioxidant effects. The antioxidant activity is considered secondary to papain's proteolytic mechanism.
Papain (a proteolytic enzyme from papaya) has been used and formally studied as a topical treatment for insect stings and bites, exploiting its ability to hydrolyze (break down) the proteinaceous venom components. Multiple US patents reference papain's established utility for hymenoptera (bee/wasp) stings, and it has been a recommended first-aid measure in medical literature.
Papain, a proteolytic enzyme from papaya (Carica papaya), has been used as an enzymatic debridement agent for burn wounds. Papain-urea preparations were historically used for burn eschar removal in clinical settings. Evidence supports papain's selective proteolysis of necrotic tissue while preserving viable burn wound tissue.
Papain is a proteolytic enzyme with documented anti-inflammatory mechanisms, including degradation of pro-inflammatory proteins and immune complexes. Multiple small clinical trials using papain alone or in enzyme blends have demonstrated reductions in postoperative swelling and pain. In vitro and animal studies support inhibition of MAPK and STAT inflammatory pathways. The overall clinical evidence in humans is promising but limited in scale.
Clinical evidence shows papain reduces post-surgical and post-traumatic pain (RxList cites 1,500 mg/day studied for this purpose). A shingles clinical study of 192 patients found enzyme therapy including papain equivalent to acyclovir for pain and skin lesions. Animal data at 50–100 mg/kg demonstrate analgesic activity via antioxidant and anti-inflammatory pathways.
The Caricol® double-blind RCT (Muss et al., 2013; n=139) found statistically significant improvement in constipation in the verum group versus placebo after 40 days of 20 mL/day. A 2021 study in Neurogastroenterology & Motility further confirmed region-specific effects of papain on gut motility relevant to constipation. These represent the strongest direct clinical evidence for this link.
Papain is a cysteine protease from Carica papaya latex with centuries of traditional use as a digestive aid in tropical medicine. It digests a broad spectrum of proteins, stimulates pancreatic trypsin activity, and modulates gut microbiota in animal models. It appears in recognized formulations for protein digestion support.
A 2024 published study (Antioxidants, PMC11351312) showed oral papain reduced atopic dermatitis severity scores, transepidermal water loss, inflammatory cytokines, serum IgE, epidermal thickness, and mast cell infiltration in a validated mouse model, alongside suppression of MAPK/STAT pathways in human keratinocytes. A second 2025 paper (MDPI, PMC12653787) confirmed papain alleviates atopic inflammation by reducing TEWL and downregulating Th2/Th17 cytokines. All current evidence is preclinical; no human clinical trials of papain specifically for eczema have been identified.
Papain, a cysteine protease from papaya, was co-administered at 95 mg/day with bromelain and ficin in two Taiwanese double-blind RCTs (n=280 and n=224) that found high-dose mixed-fruit-enzyme supplementation significantly reduced vitreous opacities over 3 months. Its proposed action is proteolytic dissolution of disorganized vitreous collagen fibrils.
Papain, a cysteine protease from papaya latex, supports digestion of dietary proteins and has been shown in animal and in vitro research to modulate gut microbiota beneficially and support mucosal integrity relevant to food sensitivity. It is commonly included in multi-enzyme digestive formulas used for protein food sensitivities.
Two clinical studies of over 150 subjects in total — including one specifically in patients with chronic stomach inflammation (gastritis) — found that papaya enzyme improved symptoms including stomach pain and inflammation versus control. Animal studies additionally show papain reduces gastric acid secretion. This constitutes meaningful scientific evidence, though study sizes are small.
Two clinical studies in IBS patients reported improvements in constipation, bloating, flatulence, and painful bowel movements with papaya enzyme. The Caricol® RCT (Muss et al., 2013; PMID 23524622) specifically recruited subjects with IBS-type symptoms and found significant improvements at 40 days. The evidence base, while genuine, is small-scale and uses papaya preparations rather than purified papain.
A clinical trial in 30 healthy volunteers found that a multi-enzyme supplement including papain reduced delayed-onset muscle soreness and prevented muscle damage after intense exercise versus placebo, with enhanced post-exercise recovery markers. The study used papain as part of an enzyme combination, limiting attribution solely to papain.
A clinical trial of 30 healthy subjects using a multi-enzyme supplement that included papain found reduced delayed-onset muscle soreness and improved post-exercise recovery versus placebo. Papain's proteolytic action on damaged proteins and inflammatory mediators underpins this effect. Evidence is limited to combination-enzyme studies.
Papain is a cysteine protease from papaya that degrades parasite cuticle proteins, contributing to documented anthelmintic activity in papaya seed preparations. It is included in digestive enzyme-based antiparasitic protocols based on its proteolytic mechanism against worm structures.
A randomized double-blind clinical trial (Menon & Muthusekhar, J Res Med Dent Sci, 2021) evaluated papain 500 mg three times daily in 60 patients after impacted third molar removal and assessed postoperative swelling and pain. An 80-patient clinical trial of a papain/bromelain/rutin combination further showed faster pain reduction and lower analgesic requirements post-surgery versus placebo. Traditional clinical use of papain for post-traumatic and post-surgical swelling is also documented.
Papain has been investigated as a topical scar treatment owing to its proteolytic degradation of excess collagen in hypertrophic scars and keloids. A 2023 PubMed study formulated papain-loaded liposomes and transferosomes for delivery across the stratum corneum specifically targeting hypertrophic scars. An earlier ScienceDirect paper on elastic liposome delivery of papain explicitly cited its role in scar management. Evidence is preclinical/formulation-stage; no controlled human RCTs on scars as a primary endpoint were identified.
A clinical study of 100 patients with sore throat and/or tonsillar inflammation found that multi-ingredient lozenges containing papaya enzyme reduced swelling, mucus, coughing, redness, and pain significantly better than placebo. Healthline also corroborates papain's role in sore throat symptom relief, noting that evidence typically involves combination treatments.
A published clinical RCT of topical 2% papain gel in venous ulcer patients (Rodrigues et al., PMC4547069; n=18, 28 ulcers, 12-week follow-up) found significant reduction in lesion area between weeks 5–12 with two complete healings. Papain is also used clinically for enzymatic debridement of chronic wounds and ulcers. Animal studies show reduced gastric ulcer size with papain treatment.
Papain is a cysteine protease from Carica papaya with documented enzymatic wound-debridement activity. Topical papain-urea preparations are used clinically to remove necrotic tissue and eschar from chronic wounds without damaging viable tissue. FDA-regulated topical preparations existed until 2008 when they were reclassified.
People with inflammatory diseases including arthritis have reported symptom relief after papain ingestion in observational contexts. Proteolytic enzymes such as papain are proposed to dissolve pathogenic immune complexes relevant to arthritis. However, no controlled human clinical trials of papain specifically for arthritis have been identified in the literature.
Papain, the proteolytic enzyme from papaya, is used as a traditional topical remedy for corns, with its enzymatic activity proposed to break down keratinized corn tissue. Multiple podiatry and natural remedy sources recommend papaya flesh or papain-containing preparations applied overnight. Evidence is based on traditional use and biological plausibility from enzymatic debridement data.
Body systems that Papain may help support.
Go back